TRABEC 1MG INJECTION is a combination of Trabectedin,
which belongs to the group of medicines called Anticancer medicines. It is used for the management of advanced soft tissue sarcoma when previous medicines have been unsuccessful, or the patients are unsuited to receiving them.
It is also used in combination with pegylated liposomal doxorubicin (another anti-cancer medicine) for the management of patients with ovarian cancer that has come back after at least 1 previous therapy and are not resistant to anti-cancer medicines containing platinum compounds.
TRABEC 1MG INJECTION is not recommended for use if you have severe liver, kidney, or heart disease. Inform your doctor if you have any kidney disease, liver disease, heart problems, or history of heart problems, Left ventricular ejection fraction (LVEF) under the lower limit of normal.
TRABEC 1MG INJECTION should not be used during pregnancy or in breastfeeding women. Consult your doctor for advice. TRABEC 1MG INJECTION is not recommended for use in children under 18 years of age with pediatric sarcomas. Consult your child’s doctor for advice.
The most common side effects of receiving TRABEC 1MG INJECTION are tiredness, difficulty breathing and coughing, pain in your back, excess of fluid in the body (oedema), bruises more easily, nose bleeds, increased risk of infections, fever, loss of appetite, nausea or vomiting, abdominal pain, diarrhea or constipation, and headache. Consult your doctor if any of the side effects worsen.
No content available
